Delta-9-tetrahydrocannabinol and cannabidiol (Sativex) with patients with moderate to severe spasticity due to multiple sclerosis
The WAR has approved a pharmacotherapeutic report for the medicine delta-9-tetrahydrocannabinol and cannabidiol (Sativex) spray for oromucosal use as adjuvant to existing treatment. In determining its therapeutic value as adjuvant to existing treatment, whereby comparison took place with placebo, they reached the following conclusion.
- the therapeutic value of Sativex as treatment to improve symptoms in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication, and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy, has a lower therapeutic value in comparison with placebo.